Pfizer FY2022 revenue record $100.3B, adj. EPS $6.58; FY2023 guidance $67-71B rev, adj. EPS $3.25-3.45

PFIZER INC

2022-FY EPS reported $5.47 revenue$100,330,000,000

Full-year 2022 revenues $100.3B (record), up 23% YoY; reported EPS $5.47, adjusted EPS $6.58.
Q4 revenues $24.3B, reported EPS $0.87, adjusted EPS $1.14.
FY2023 revenue guidance $67-71B (down ~31%), adjusted EPS $3.25-3.45 (down ~49% operational).
Excluding COVID products, Pfizer expects 7-9% operational revenue growth in 2023.
Completed ~$26B in acquisitions in 2022 (Biohaven, Arena, GBT); $9B dividends, $2B share repurchases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported Full-Year 2022 results: revenue $100.3 Billion, EPS $5.47.

Period: Full-Year 2022
Revenue: $100.3 Billion
EPS: $5.47
Result: reported results

Exact text from the filing

Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 2% Operationally ▪ Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported Full-Year 2023 results: revenue $67.0 to $71.0 Billion, EPS $3.25 to $3.45. Guidance initiated.

Period: Full-Year 2023
Revenue: $67.0 to $71.0 Billion
EPS: $3.25 to $3.45
Guidance: initiated
Result: guidance update

Exact text from the filing

▪ Provides Full-Year 2023 Revenue Guidance (4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS (3) Guidance of $3.25 to $3.45

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PFIZER INC reported Fourth-Quarter 2022 results: revenue $24.3 Billion, EPS $0.87.

Period: Fourth-Quarter 2022
Revenue: $24.3 Billion
EPS: $0.87
Result: reported results

Exact text from the filing

Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer ▪ Fourth-Quarter 2022 Reported Diluted EPS (2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS (3) of $1.14, Up 45% Year-Over-Year

View on SEC.gov

Browse all earnings releases →

PFIZER INC filing history →

Source: SEC EDGAR

accession 0000078003-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.